Pluri Inc. (NASDAQ:PLUR) Sees Significant Growth in Short Interest
by Danessa Lincoln · The Markets DailyPluri Inc. (NASDAQ:PLUR – Get Free Report) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 26,450 shares, a growth of 70.5% from the August 15th total of 15,514 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average trading volume of 37,865 shares, the short-interest ratio is currently 0.7 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.
View Our Latest Analysis on Pluri
Pluri Trading Up 0.9%
PLUR traded up $0.01 during trading hours on Friday, hitting $1.09. 6,183 shares of the company’s stock were exchanged, compared to its average volume of 17,354. The firm has a market cap of $13.46 million, a P/E ratio of -0.44 and a beta of 0.68. Pluri has a 12-month low of $1.06 and a 12-month high of $4.87. The firm has a 50 day moving average of $1.58 and a 200 day moving average of $2.43.
Pluri (NASDAQ:PLUR – Get Free Report) last posted its quarterly earnings results on Thursday, September 10th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.12. The business had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.66 million.
About Pluri
Pluri Ltd. is an Israel-based biotechnology company that develops cell-based products using its proprietary three-dimensional cell expansion technology. The platform is designed to produce large quantities of potentially therapeutic and commercial cells while maintaining consistent quality and scalability.
The company’s research and development activities have included placenta-derived, off-the-shelf cell therapies, historically marketed under the PLX platform. These programs have targeted areas such as regenerative medicine, inflammation, cancer, orthopedic conditions and other medical needs.